Everest Medicines 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
188 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zetomipzomib (KZR-616) / Kezar
NCT04628936 / 2020-004382-39: Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Completed
2
18
US, RoW
KZR-616, KZR-616 Lyophile, zetomipzomib
Kezar Life Sciences, Inc., Kezar life Sciences, Inc.
Polymyositis, Dermatomyositis
03/23
06/23
2020-004382-39: This is an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active polymyositis or dermatomyositis who completed the double-blind treatment period of Study KZR-616-003 (EudraCT Number: 2019-002605-22), up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616.

Not yet recruiting
2
24
RoW
KZR-616, Lyophilisate for solution for injection
Kezar Life Sciences, Inc., Kezar life Sciences, Inc.
Autoimmune Disorders Polymyositis and Dermatomyositis, inflammation of the muscles; inflammation of the skin, Diseases [C] - Immune System Diseases [C20]
 
 
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Completed
2
24
US
zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension
Kezar Life Sciences, Inc.
Autoimmune Hepatitis
04/25
04/25
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
ACTRN12618002060224: A Phase 1, Randomised, Double-Blind, placebo controlled, single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of KZR-616 in healthy female subjects.

Not yet recruiting
1
72
 
Clinical Netwprk Services, Kezar Life Sciences
Chronic inflammatory conditions for example rheumatoid arthritis, Autoimmune disorders for example systemic lupus erythematosus
 
 
Tarpeyo (budesonide) / Calliditas, Stada
NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Recruiting
4
60
US
TARPEYO®, delayed-release budesonide capsules
Calliditas Therapeutics AB, Worldwide Clinical Trials
IgA Nephropathy
05/26
11/27
BAIN, NCT07030894: Nefecon and Ambrisentan in IgA Nephropathy

Not yet recruiting
4
129
NA
"Nefecon®","Ambrisentan"
The First Hospital of Jilin University
IgA Nephropathy, Chronic Kidney Disease, Proteinuria
12/26
12/26
Nefigard, NCT03643965 / 2017-004902-16: Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Completed
3
365
Europe, Canada, US, RoW
Nefecon, Budesonide modified released capsule, Placebo oral capsule, Placebo
Calliditas Therapeutics AB
Primary IgA Nephropathy
07/23
07/23
Nefigard-OLE, NCT04541043 / 2020-003308-14: Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301

Completed
3
119
Europe, Canada, US, RoW
Nefecon 16mg daily
Calliditas Therapeutics AB
Primary IgA Nephropathy
02/24
02/24
NCT05534919: Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

Completed
3
21
RoW
Nefecon
Everest Medicines (Singapore) Pte. Ltd.
Primary Immunoglobulin a Nephropathy (IgAN)
07/24
07/24
NCT06922305: Relative Bioavailability Study of HR19042 in Healthy Subjects

Completed
1
18
RoW
HR19042 Capsule, Tarpeyo®, Budenofalk®
Jiangsu HengRui Medicine Co., Ltd.
Primary IgA Nephropathy; Autoimmune Hepatitis
01/24
01/24
NCT06589752: Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

Completed
N/A
200
RoW
TARPEYO 4 MG Delayed Release Oral Capsule, RAS inhibitor
Ruijin Hospital
Primary IgA Nephropathy
09/24
09/24
Velsipity (etrasimod) / Pfizer
ES101002, NCT04176588: A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

Hourglass Jul 2024 - Dec 2024 : Maintenance data for moderately-to-severely active ulcerative colitis
Hourglass Dec 2023 - Dec 2023 : Completion of enrollment in phase 3 study of moderate-severe ulcerative colitis
Active, not recruiting
3
341
RoW
Etrasimod, Placebo
Everstar Therapeutics Limited
Moderately to Severely Active Ulcerative Colitis
07/24
10/24
ELEVATE UC OLE, NCT03950232 / 2018-003987-29: An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Etrasimod, APD334
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Ulcerative Colitis
06/29
06/29
CULTIVATE, NCT04173273 / 2019-002895-14: A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

Hourglass Apr 2022 - Jun 2022 : Data from sub-study A of P2/3 CULTIVATE trial for Crohn’s disease
Active, not recruiting
3
375
Europe, Canada, Japan, US, RoW
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Crohn's Disease
04/25
08/29
2020-004775-40: A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's Disease

Ongoing
2/3
1265
Europe, RoW
Etrasimod, APD334, Tablet
Arena Pharmaceuticals Inc., ARENA PHARMACEUTICALS, INC., Arena Pharmaceuticals Inc.
Crohn's Disease, Crohn's Disease a form of inflammatory bowel disease., Diseases [C] - Digestive System Diseases [C06]
 
 
2022-003361-37: A Study of Etrasimod in Adults With Moderate-to-Severe Atopic Dermatitis, Who Have Tried Prior Systemic Treatments for Atopic Dermatitis. Studie přípravku Etrasimod u dospělých se středně těžkou až těžkou formou atopické dermatitidy, kteří dříve selhali na systémové léčbě atopické dermatitidy

Not yet recruiting
2/3
400
RoW
etrasimod, PF-07915503, Tablet
Pfizer Inc., Pfizer INc.
Moderate-to-Severe Atopic Dermatitis with a History of Prior Systemic Treatment Failure, Atopic Dermatitis, Diseases [C] - Immune System Diseases [C20]
 
 
NCT05033340: The Efficacy and Safety of Oral Etrasimod as Therapy for Moderately to Severely Active Crohn's Disease

Not yet recruiting
2/3
5
NA
Etrasimod, APD334, Placebo, PLEACEBO
Samia Hassan El-Shishtawy, Arena Pharmaceuticals
Crohn Disease
08/25
08/25
NCT05732454 / 2022-003361-37: A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Terminated
2/3
58
Europe, Canada, US, RoW
etrasimod, APD334, PF-07915503, Placebo
Pfizer, Pfizer INc.
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
04/24
04/24
VOYAGE, NCT04682639 / 2020-003226-23: A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

Completed
2
108
Europe, Canada, US, RoW
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Eosinophilic Esophagitis
09/22
06/23
NCT04556734: Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

Completed
2
80
Canada, US
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Alopecia Areata
06/23
06/23
2020-003226-23: A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with eosinophilic esophagitis

Not yet recruiting
2
96
Europe
Etrasimod, APD334, Tablet
Arena Pharmaceuticals Inc., Arena Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer Inc., Arena Pharmaceuticals Inc.
Eosinophilic Esophagitis (EoE), Eosinophilic esophagitis (EoE) a chronic, allergic inflammatory disease of the esophagus (the tube connecting the mouth to the stomach)., Diseases [C] - Digestive System Diseases [C06]
 
 
NCT05061446: Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Completed
2
54
Japan
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Ulcerative Colitis
10/23
10/23
GLADIATOR UC, NCT04607837 / 2020-003507-34: Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

Checkmark Initiation of GLADIATOR UC trial in ulcerative colitis
May 2021 - May 2021: Initiation of GLADIATOR UC trial in ulcerative colitis
Completed
2
234
Europe, Canada, US, RoW
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Ulcerative Colitis
06/24
06/24
NCT06521762: Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis

Recruiting
2
96
US
Etrasimod, VELSIPITY, Placebo, Corticosteroids
Yale University, Pfizer
Immune Checkpoint Inhibitor-Related Diarrhea and Colitis
12/28
12/28
NCT05287126: A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Recruiting
2
36
Europe, Japan, US
Etrasimod, APD334
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Ulcerative Colitis
07/27
08/31
NCT03894163: A Phase I Study of Etrasimod in Healthy Chinese Audlt Subjects.

Recruiting
1
36
RoW
Etrasimod, Etrasimod Placebo
Everstar Therapeutics Limited
Healthy Volunteers
06/19
10/19
NCT06140290: A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Completed
1
8
Europe
Etrasimod Immediate Release (IR)
Pfizer
Healthy Participants
03/24
03/24
NCT05956002: A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants

Completed
1
16
Europe
Estraimod Immediate Release (IR), Etrasimod Mini Tab in water, Etrasimod Mini Tab in chocolate pudding, Etrasimod Mini Tab in yogurt, Etrasimod Mini Tab in applesauce
Pfizer
Healthy Participants
01/24
01/24
NCT06025227: Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.

Available
N/A
NA
Etrasimod
Pfizer, In Expanded Access, treating physicians are the Sponsors
Colitis, Ulcerative
 
 
EFFECT-UC, NCT06294925: A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

Recruiting
N/A
360
Europe, Canada
Etrasimod
Pfizer
Colitis, Ulcerative
04/27
05/27
ENDEAVOUR-UC, NCT06398626: An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Recruiting
N/A
300
US
Etrasimod
Pfizer
Colitis, Ulcerative
05/27
09/27
Trodelvy (sacituzumab govitecan-hziy) / Gilead
NCT04319198 / 2019-004868-22: Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Completed
4
25
Europe, US
Sacituzumab Govitecan-hiy, IMMU-132, Trodelvy™, GS-0132
Gilead Sciences, Immunomedics, Inc., Gilead Sciences Inc.
Metastatic Solid Tumor
10/24
10/24
2019-004868-22: Open-label Rollover Study to Assess Long-Term Safety in Subjects with Metastatic Cancers that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan.

Not yet recruiting
3
200
Europe
Sacituzumab govitecan, IMMU-132, hRS7-SN38, Lyophilisate for solution for infusion
Immunomedics, Inc., Gilead Sciences Inc, Immunomedics, Inc., Gilead Sciences Inc.
Metastatic Solid Tumors, Metastatic Cancer, Diseases [C] - Cancer [C04]
 
 
2019-004100-35: Therapy with an antibody-drug conjugate in patients with early HER2-negative breast cancer and high risk of relapse after neoadjuvant chemotherapy in primary HER2-negative breast cancer patients Therapie mit einem Antikörper-Wirkstoff-Konjugat bei Patienten mit frühem HER2-negativem Mammakarzinom und hohem Rückfallrisiko nach einer neoadjuvanten Chemotherapie bei primären HER2-negativen Brustkrebspatienten.

Ongoing
3
1200
Europe
Sacituzumab Govitecan, IMMU-132, Lyophilisate for solution for infusion
GBG Forschungs GmbH, Immunomedics, Inc, Gilead Sciences/Immunomedics, Inc
HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment HER2-negativem Brustkrebs und hohem Rückfallrisiko nach einer Standardbehandlung im neoadjuvanten Setting, HER2-negative breast cancer HER2-negativem Brustkrebs, Diseases [C] - Cancer [C04]
 
 
2021-003578-30: A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Estudio de sacituzumab govitecán frente a docetaxel en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado o metastásico

Not yet recruiting
3
580
Europe
Sacituzumab govitecan, Docetaxel, L01CD02, Powder for solution for infusion, Concentrate for solution for infusion, Docetaxel
Gilead Sciences, Inc., GILEAD SCIENCES INCORPORATED, Gilead Sciences, Inc.
Non-Small Cell Lung Cancer Cáncer de Pulmón No Microcítico, Non-Small Cell Lung Cancer Cáncer de Pulmón No Microcítico, Diseases [C] - Cancer [C04]
 
 
2022-000836-49: Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK-3475 for PD-L1 TPS ≥50% Metastatic NSCLC

Not yet recruiting
3
614
Europe
Solution for infusion, Powder for solution for infusion, KEYTRUDA (pembrolizumab, MK-3475), Trodelvy
Merck Sharp & Dohme LLC, MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.
First-line treatment of metastatic programmed cell death ligand 1 expressing (tumor proportion score ≥50%) non-small cell lung cancer, Previously untreated metastatic non-small cell lung cancer with tumors expressing PD-L1 ≥ 50%, Diseases [C] - Cancer [C04]
 
 
EVER-132-002, NCT04639986: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruiting
3
331
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Eribulin Mesylate Injection, Halaven, Capecitabine Oral Product, Xeloda, Gemcitabine Injection, Gemzar, Vinorelbine injection, Navelbine
Gilead Sciences, Iqvia Pty Ltd, Medidata Solutions, Parexel
Metastatic Breast Cancer
12/25
12/25
EVOKE-01, NCT05089734 / 2021-003578-30: Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Jan 2023 - Dec 2024: Data from EVOKE-01 trial for advanced or metaststic NSCLC in 2024
Hourglass Jan 2023 - Jun 2023 : Enrollment completion of EVOKE-01 trial for advanced or metaststic NSCLC
Active, not recruiting
3
603
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan-hziy (SG), IMMU-132, GS-0132, Docetaxel
Gilead Sciences, Gilead Sciences, Inc.
Non-Small Cell Lung Cancer
11/23
01/26
TROPiCS-04, NCT04527991 / 2020-002964-29: Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Jan 2024 - Dec 2024: Data readout from TROPiCS-04 trial for 2L metastatic urothelial cancer
Hourglass Jan 2021 - Jun 2021 : Regulatory submission in US for 3L urothelial carcinoma (based on TROPHY U-01 trial)
Active, not recruiting
3
696
Europe, Canada, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Paclitaxel, Taxol®, Docetaxel, Taxotere®, Vinflunine, Javlor ®
Gilead Sciences, Everest Medicines
Locally Advanced or Metastatic Unresectable Urothelial Cancer
10/25
10/25
ASCENT-GYN-01, NCT06486441: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (/GOG-3104/ENGOT-en26)

Recruiting
3
520
Europe, Canada, Japan, US, RoW
Sacituzumab govitecan-hziy, Trodelvy™, GS-0132, Doxorubicin, Adriamycin, Paclitaxel, Taxol
Gilead Sciences, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Endometrial Cancer
06/29
06/29
TROPiCS-02, NCT03901339 / 2018-004201-33: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Jul 2023 - Dec 2023: Regulatory decision in EU for HR+/HER2 breast cancer
Checkmark Approved for unresectable, locally advanced or metastatic HR+, HER2-ve metastatic breast cancer based on data from TROPiCS-02 study
Feb 2023 - Feb 2023: Approved for unresectable, locally advanced or metastatic HR+, HER2-ve metastatic breast cancer based on data from TROPiCS-02 study
Checkmark EMA validated MAA for Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
Jan 2023 - Jan 2023: EMA validated MAA for Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
More
Completed
3
543
Europe, Canada, US
Sacituzumab Govitecan-hziy, IMMU-132, GS-0132, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Gilead Sciences
Metastatic Breast Cancer
10/23
10/23
ISIdE, NCT05552001: Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

Recruiting
3
96
Europe
Sacituzumab govitecan, trodelvy
UNICANCER, Gilead Sciences
Triple Negative Breast Cancer, Metastatic Breast Cancer
05/26
05/28
ARIAN, NCT06431633: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Recruiting
3
129
Europe
Zimberelimab, anti-PD-1 monoclonal antibody AB122, Sacituzumab govitecan, Trodelvy, Cisplatin, Platinol, Carboplatin, Paraplatin
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma
11/31
11/31
EVOKE-SCLC-04, NCT06801834: Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Recruiting
3
695
Japan, US, RoW
Sacituzumab Govitecan (SG), Trodelvy®, GS-0132, IMMU 132, Topotecan, Amrubicin (Japan only)
Gilead Sciences
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
10/29
10/29
EA8231, NCT06524544: A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Sacituzumab Govitecan Alone in the Treatment of Advanced Urothelial Cancer

Not yet recruiting
3
384
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Questionnaire Administration, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy
National Cancer Institute (NCI)
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
12/28
12/28
ASCENT-07, NCT05840211: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan-hziy, Trodelvy™, GS-0132, IMMU-132, Paclitaxel, Taxol®, Nab-paclitaxel, Abraxane®, Capecitabine, Xeloda®
Gilead Sciences
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
09/25
12/28
KEYNOTE D46, NCT05609968 / 2022-000836-49: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Calendar Jan 2025 - Dec 2025: Market entry for mTNBC
Recruiting
3
614
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan, Trodelvy®, Pembrolizumab, MK-3475, Keytruda®
Merck Sharp & Dohme LLC, Gilead Sciences
Carcinoma, Non-Small-Cell Lung
01/27
08/28
ASCENT-04, NCT05382286 / 2021-005742-14: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting
3
443
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Pembrolizumab, KEYTRUDA®, Paclitaxel, Taxol®, nab-Paclitaxel, Abraxane®, Gemcitabine, Gemzar, Carboplatin
Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer, PD-L1 Positive
02/27
02/27
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ASCENT-05, NCT05633654: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Recruiting
3
1514
Europe, US, RoW
Sacituzumab govitecan-hziy (SG), GS-0132, IMMU-132, Trodelvy™, Pembrolizumab, KEYTRUDA®, Capecitabine, Xeloda
Gilead Sciences, Alliance Foundation Trials, LLC., NSABP Foundation Inc, GBG Forschungs GmbH
Triple Negative Breast Cancer
06/27
08/31
SWOG S1937, NCT04579224: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Recruiting
3
184
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy
National Cancer Institute (NCI)
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
08/30
08/30
ASCENT-03, NCT05382299 / 2021-005743-79: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Hourglass Jul 2024 - Dec 2024 : Data readout for 1L mTNBC (PD-L1)
Hourglass Aug 2024 - Dec 2024 : Data for 1L mTNBC (PD-L1-)
Recruiting
3
540
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Paclitaxel, nab-Paclitaxel, Abraxane®, Gemcitabine, Carboplatin
Gilead Sciences, Gilead Sciences, Inc
Triple Negative Breast Cancer, PD-L1 Negative
07/28
07/28
TROPHIT1, NCT06243393: Sacituzumab Govitecan in Metastatic Colorectal Cancer

Recruiting
2/3
80
Europe
Sacituzumab Govitecan (SG), Physicians Choice (PhC).
University Hospital Heidelberg
Metastatic Colorectal Cancer
08/28
02/29
2020-004844-27: Neoadjuvant sacituzumab govitecan to treat muscle-invasive bladder cancer Terapia neoadiuvante con sacituzumab govitecan per trattare cancro della vescica muscolo-infiltrante

Not yet recruiting
2
56
Europe
sacituzumab govitecan, [IMMU-132], Lyophilisate for solution for infusion
OSPEDALE SAN RAFFAELE, Immunomedics, Inc.
Muscle-invasive bladder cancer Cancro della vescica muscolo-infiltrante, Bladder cancer Cancro della vescica, Diseases [C] - Cancer [C04]
 
 
EVER-132-001, NCT04454437: Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Checkmark Approved in China for 2L metastatic TNBC
Jun 2022 - Jun 2022: Approved in China for 2L metastatic TNBC
Checkmark Submitted NDA in Hong Kong for the treatment of unresectable locally advanced or metastatic TNBC
Mar 2022 - Mar 2022: Submitted NDA in Hong Kong for the treatment of unresectable locally advanced or metastatic TNBC
Hourglass Aug 2021 - Dec 2021 : Submit BLA for metastatic TNBC in Taiwan and South Korea
More
Active, not recruiting
2
80
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132
Gilead Sciences, IQVIA RDS (Shanghai) Co., Ltd., Medidata Solutions, Q Squared Solutions (Beijing) Co., Ltd, Parexel
Metastatic Triple-negative Breast Cancer
08/21
12/25
2020-004876-16: SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy SURE-02: Studio di Fase 2, in aperto, a singolo braccio, con anticorpo immunoconiugato sacituzumab govitecan, in associazione a pembrolizumab, in pazienti con carcinoma uroteliale della vescica muscolo-infiltrante che non possono ricevere o che rifiutano la chemioterapia con cisplatino.

Ongoing
2
48
Europe
Pembrolizumab, Sacituzumab Govitecan, [NA], [IMMU-132], Solution for infusion, Lyophilisate for solution for infusion, KEYTRUDA (Pembrolizumab, MK-3475)
OSPEDALE SAN RAFFAELE, Merck Sharp & Dohme Corp., Immunomedics, Inc.
muscle-invasive bladder cancer Carcinoma uroteliale della vescica muscolo infiltrante, muscle-invasive bladder cancer Carcinoma uroteliale della vescica muscolo infiltrante, Diseases [C] - Cancer [C04]
 
 
2019-000579-18: A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Un estudio de sacituzumab govitecan (IMMU-132) en pacientes con tumores sólidos metastásicos

Not yet recruiting
2
420
Europe
sacituzumab govitecan, Powder for solution for infusion, Trodelvy
Gilead Sciences, Inc., Gilead Sciences, Inc.
Metastatic Solid Tumors Tumores sólidos metastásicos, Metastatic Solid Tumors Tumores sólidos metastásicos, Diseases [C] - Cancer [C04]
 
 
2021-003669-36: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruiting
2
280
Europe
BAVENCIO, sacituzumab govitecan, MSB0010718C, IMMU-132, M6223, NKTR-255, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, BAVENCIO, Trodelvy
Merck Healthcare KGaA, MERCK KGAA, Merck Healthcare KGaA
Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy., Bladder cancer, Diseases [C] - Cancer [C04]
 
 
2022-001397-61: Clinical trial phase II with Sacituzumab govitecan in Patients with Metastatic Triple-Negative Breast Cancer Ensayo clínico fase II con Sacituzumab govitecan para pacientes con cancer de mama triple negativo

Not yet recruiting
2
50
Europe
Trodelvy, EU/1/21/1592/001, Powder for concentrate for solution for infusion
Medica Scientia Innovation Research SL., Gilead Sciencies SLU
Advanced triple-negative breast cancer Cáncer de mama triple negativo avanzado, Advanced triple-negative breast cancer (TNBC) Cáncer de mama triple negativo avanzado (TNBC), Diseases [C] - Cancer [C04]
 
 
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
SURE-01, NCT05226117: Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Recruiting
2
44
Europe
Sacituzumab govitecan
IRCCS San Raffaele, High Research
Urothelial Carcinoma
06/25
06/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
NCT04251416: A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Recruiting
2
50
US
Sacituzumab Govitecan, IMMU-132
Yale University, Gilead Sciences
Endometrial Carcinoma
12/25
02/26
NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting
2
40
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
08/26
NCT06178588: Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Recruiting
2
22
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
University of Kansas Medical Center, National Cancer Institute (NCI)
Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
11/25
11/26
ACROSS-TROP2, NCT06236269: HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

Recruiting
2
50
Europe
Sacituzumab Govitecan, Trodelvy
SOLTI Breast Cancer Research Group
Breast Cancer Stage IV
02/26
02/27
NCT05675579: A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Recruiting
2
25
US
Sacituzumab Govitecan, (IMMU-132) Immunomedics, Pembrolizumab, KEYTRUDA®
M.D. Anderson Cancer Center, Gilead Sciences
Breast Cancer
12/26
12/26
Saci-IO TNBC, NCT04468061: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Hourglass Jan 2022 - Jun 2022 : Initiation of P3 trial in combination with keytruda for 1L mTNBC
Recruiting
2
110
US
Sacituzumab Govitecan, IMMU-132, Trodelvy, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Gilead Sciences, Merck Sharp & Dohme LLC
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
04/26
04/29
NCT06248515: A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Recruiting
2
18
US
Sacituzumab govitecan-hziy
Georgetown University, Gilead Sciences
Thymoma, Thymic Carcinoma
04/26
12/26
TROPICS-03, NCT03964727 / 2019-000579-18: Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

Hourglass Jun 2023 - Jun 2023 : Presentation of data from TROPiCS-03 trial for advanced/metastatic endometrial cancer at ASCO 2023
Hourglass Jan 2022 - Dec 2022 : From TROPiCS-03 trial for NSCLC
Active, not recruiting
2
227
Europe, Canada, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, GS-0132
Gilead Sciences, Gilead Sciences, Inc.
Metastatic Solid Tumor
01/25
09/25
NCT04986579: Scalp Cooling in MBC

Recruiting
2
120
US
Paxman Scalp Cooling System, Scalp Cooling Cap, Eribulin, Halaven, Sacituzumab govitecan, Trodelvy, IMMU-132, Trastuzumab deruxtecan, Enhertu, DS-8201a
Dana-Farber Cancer Institute, Paxman Coolers Limited, AstraZeneca, Eisai Inc., Daiichi Sankyo, Gilead Sciences
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
06/26
06/28
NCT06462079: Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Not yet recruiting
2
43
NA
Sacituzumab Govitecan, Trodelvy, Radiotherapy
Guangzhou Medical University
Brain Metastasis
01/27
07/27
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
NCT06477419: A Study of Sacituzumab Govitecan in People With Mesothelioma

Recruiting
2
33
US
Sacituzumab govitecan-hziy
Memorial Sloan Kettering Cancer Center, Gilead Sciences
Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
06/29
06/29
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Laura Huppert, MD, BA, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/26
06/26
TROPHY-U-01, NCT03547973 / 2018-001167-23: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Hourglass Jun 2023 - Jun 2023 : Presentation of data from TROPHY U-01 trial for metastatic urothelial cancer at ASCO 2023
Checkmark Approved in US for 3L metastatic urothelial cancer
Apr 2021 - Apr 2021: Approved in US for 3L metastatic urothelial cancer
Checkmark Data from TROPHY U-01 study in combination with pembrolizumab for 2L metastatic urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: Data from TROPHY U-01 study in combination with pembrolizumab for 2L metastatic urothelial cancer at ESMO 2020
More
Recruiting
2
827
Europe, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, Pembrolizumab, KEYTRUDA®, Cisplatin, Avelumab, BAVENCIO®, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
Gilead Sciences, Merck KGaA, Darmstadt, Germany
Metastatic Urothelial Cancer
06/30
06/30
NCI-2018-02551, NCT03725761: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Active, not recruiting
2
31
US
Sacituzumab Govitecan, IMMU-132
University of Wisconsin, Madison, National Cancer Institute (NCI), Gilead Sciences
Prostate Cancer
04/24
09/27
ELEVATE TNBC, NCT04958785: Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Terminated
2
92
Europe, US, RoW
Magrolimab, GS-4721, Nab-Paclitaxel, Abraxane, Paclitaxel, Taxol®, Sacituzumab Govitecan-hziy, GS-0132, Trodelvy®
Gilead Sciences
Triple-Negative Breast Cancer
10/24
10/24
EVOKE-02, NCT05186974 / 2021-004280-27: Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Hourglass Jul 2021 - Jun 2022 : Market entry for mTNBC
Active, not recruiting
2
193
Europe, Canada, US, RoW
Sacituzumab Govitecan-hziy (SG), GS-0132, IMMU-132, Pembrolizumab, KEYTRUDA®, Carboplatin, Paraplatin®, Cisplatin, Platinol®
Gilead Sciences, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
02/26
02/26
SG-ESCC, NCT06329869: Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
35
RoW
Sacituzumab govitecan
National Taiwan University Hospital, Gilead Sciences
Esophageal Squamous Cell Carcinoma
11/26
11/27
SMART, NCT06161532: Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors () Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Recruiting
2
60
US
Sacituzumab govitecan, Atezolizumab
National Cancer Institute (NCI)
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract, Primary Adenocarcinoma of the Bladder, Primary Adenocarcinoma of the Urinary Tract, Renal Medullary Carcinoma, Squamous Cell Carcinoma of the Penis
11/27
11/28
SETHY, NCT06235216: Sacituzumab govitEcan in THYroid Cancers

Recruiting
2
42
Europe
Sacituzumab govitecan, Trodelvy
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
12/27
12/27
NCT06739395: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting
2
300
RoW
Olaparib tablet, Temozolomide capsule, Anlotinib, Trametinib tablet, Dabrafenib, Vebreltinib Enteric Capsules, Alpelisib Pill, Sacituzumab Govitecan-Hziy 180 MG, Lenvatinib Capsules, Pazopanib Pill, Palbociclib Pill, Chidamide, PD-1/PD-L1/PD-1&CTLA4 inhibitor, Target Gene
Tianjin Medical University Second Hospital
Solid Tumor, Precision Medicine
12/26
05/27
NCT06682728: Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Recruiting
2
23
US
Sacituzumab Govitecan (SG), Nivolumab
University of California, Irvine, Gilead Sciences
Urothelial Carcinoma, Muscle-invasive Bladder Cancer
12/26
12/26
preSAVE, NCT06528483: Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

Not yet recruiting
2
63
Europe
Sacituzumab Govitecan + Zimberelimab, TRODELVY, AB122
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Gilead Sciences
Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm, Muscle-Invasive Bladder Carcinoma
12/26
12/29
NCT06878625: A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Recruiting
2
138
RoW
Sacituzumab Govitecan combined with Toripalimab, Sacituzumab govitecan combined with anti-angiogenesis
Tianjin Medical University Cancer Institute and Hospital
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
06/27
06/27
NCT06667167: First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

Recruiting
2
21
RoW
Induction Carboplatin, Carboplatin, Etoposide, Pembrolizumab, Sacituzumab Govitecan
Nir Peled
NSCLC (non-small Cell Lung Cancer)
11/27
11/28
NCI-2018-01581, NCT03606967: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
2
70
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Personalized Synthetic Long Peptide Vaccine, Personalized SLP Vaccine, TSMA-based SLP Vaccine, TSMA-based Synthetic Long Peptide Vaccine, Tumor Specific Mutant Antigen-based Synthetic Long Peptide Vaccine, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
11/25
11/25
NCT05884320: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Recruiting
2
30
US
Sacituzumab Govitecan
M.D. Anderson Cancer Center, Gilead Sciences
Gland, Salivary Gland Cancers
12/25
12/26
NCT06133517: PeRioperative Immunotherapy Combined with Sacituzumab Govitecan in Muscle Invasive BlAdder Cancer

Recruiting
2
70
Europe
Sacituzumab govitecan, Trodelvy, Zimberelimab, Domvanalimab
Fundación para el Progreso de la Oncología en Cantabria, Apices Soluciones S.L.
Urothelial Bladder Carcinoma
12/30
12/30
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
06/25
07/26
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Active, not recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
NCT06311214: Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Recruiting
2
500
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Electronic Health Record Review, Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG 22CE, ASG-22CE, ASG22CE, Enfortumab Vedotin-ejfv, Padcev, Immunohistochemistry Staining Method, Cell/Tissue, Immunohistochemistry, IHC, Immunohistochemistry, Immunohistochemistry (IHC), Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
03/28
03/28
NCT06665178: Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Recruiting
2
20
Canada
Sacituzumab Govitecan
British Columbia Cancer Agency, Gilead Sciences
Breast Cancer
05/27
12/28
TROP2, NCT06923826: Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

Not yet recruiting
2
32
RoW
Sacituzumab govitecan, Trodelvy
National University Hospital, Singapore, Gilead Sciences
Salivary Gland Cancer, Thyroid Cancer
04/30
04/30
NCT06401824: Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Recruiting
2
25
Europe
Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab, sacituzumab govitecan; zirabev
Maastricht University Medical Center, Gilead Sciences
NSCLC Stage IV, Brain Metastases, Adult
11/26
04/27
Saci-IO HR+, NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Hourglass Jan 2021 - Jan 2021 : Data from trial for HR+ / HER2 – metastatic breast cancer
Active, not recruiting
2
110
US
Pembrolizumab, Keytruda, Sacituzumab Govitecan, TRODELVY
Ana C Garrido-Castro, MD, Merck Sharp & Dohme LLC, Gilead Sciences
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
03/24
06/27
NCT07040644: A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Not yet recruiting
2
150
RoW
Sacituzumab Govitecan (SG), Toripalimab, Nab-paclitaxel
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple Negative Breast Neoplasms
06/27
06/28
NCT06865677: Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Suspended
2
95
US
Sacituzumab govitecan
National Cancer Institute (NCI)
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
04/27
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zetomipzomib (KZR-616) / Kezar
NCT04628936 / 2020-004382-39: Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Completed
2
18
US, RoW
KZR-616, KZR-616 Lyophile, zetomipzomib
Kezar Life Sciences, Inc., Kezar life Sciences, Inc.
Polymyositis, Dermatomyositis
03/23
06/23
2020-004382-39: This is an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active polymyositis or dermatomyositis who completed the double-blind treatment period of Study KZR-616-003 (EudraCT Number: 2019-002605-22), up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616.

Not yet recruiting
2
24
RoW
KZR-616, Lyophilisate for solution for injection
Kezar Life Sciences, Inc., Kezar life Sciences, Inc.
Autoimmune Disorders Polymyositis and Dermatomyositis, inflammation of the muscles; inflammation of the skin, Diseases [C] - Immune System Diseases [C20]
 
 
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Completed
2
24
US
zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension
Kezar Life Sciences, Inc.
Autoimmune Hepatitis
04/25
04/25
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
ACTRN12618002060224: A Phase 1, Randomised, Double-Blind, placebo controlled, single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of KZR-616 in healthy female subjects.

Not yet recruiting
1
72
 
Clinical Netwprk Services, Kezar Life Sciences
Chronic inflammatory conditions for example rheumatoid arthritis, Autoimmune disorders for example systemic lupus erythematosus
 
 
Tarpeyo (budesonide) / Calliditas, Stada
NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Recruiting
4
60
US
TARPEYO®, delayed-release budesonide capsules
Calliditas Therapeutics AB, Worldwide Clinical Trials
IgA Nephropathy
05/26
11/27
BAIN, NCT07030894: Nefecon and Ambrisentan in IgA Nephropathy

Not yet recruiting
4
129
NA
"Nefecon®","Ambrisentan"
The First Hospital of Jilin University
IgA Nephropathy, Chronic Kidney Disease, Proteinuria
12/26
12/26
Nefigard, NCT03643965 / 2017-004902-16: Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Completed
3
365
Europe, Canada, US, RoW
Nefecon, Budesonide modified released capsule, Placebo oral capsule, Placebo
Calliditas Therapeutics AB
Primary IgA Nephropathy
07/23
07/23
Nefigard-OLE, NCT04541043 / 2020-003308-14: Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301

Completed
3
119
Europe, Canada, US, RoW
Nefecon 16mg daily
Calliditas Therapeutics AB
Primary IgA Nephropathy
02/24
02/24
NCT05534919: Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

Completed
3
21
RoW
Nefecon
Everest Medicines (Singapore) Pte. Ltd.
Primary Immunoglobulin a Nephropathy (IgAN)
07/24
07/24
NCT06922305: Relative Bioavailability Study of HR19042 in Healthy Subjects

Completed
1
18
RoW
HR19042 Capsule, Tarpeyo®, Budenofalk®
Jiangsu HengRui Medicine Co., Ltd.
Primary IgA Nephropathy; Autoimmune Hepatitis
01/24
01/24
NCT06589752: Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

Completed
N/A
200
RoW
TARPEYO 4 MG Delayed Release Oral Capsule, RAS inhibitor
Ruijin Hospital
Primary IgA Nephropathy
09/24
09/24
Velsipity (etrasimod) / Pfizer
ES101002, NCT04176588: A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

Hourglass Jul 2024 - Dec 2024 : Maintenance data for moderately-to-severely active ulcerative colitis
Hourglass Dec 2023 - Dec 2023 : Completion of enrollment in phase 3 study of moderate-severe ulcerative colitis
Active, not recruiting
3
341
RoW
Etrasimod, Placebo
Everstar Therapeutics Limited
Moderately to Severely Active Ulcerative Colitis
07/24
10/24
ELEVATE UC OLE, NCT03950232 / 2018-003987-29: An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Etrasimod, APD334
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Ulcerative Colitis
06/29
06/29
CULTIVATE, NCT04173273 / 2019-002895-14: A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

Hourglass Apr 2022 - Jun 2022 : Data from sub-study A of P2/3 CULTIVATE trial for Crohn’s disease
Active, not recruiting
3
375
Europe, Canada, Japan, US, RoW
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Crohn's Disease
04/25
08/29
2020-004775-40: A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's Disease

Ongoing
2/3
1265
Europe, RoW
Etrasimod, APD334, Tablet
Arena Pharmaceuticals Inc., ARENA PHARMACEUTICALS, INC., Arena Pharmaceuticals Inc.
Crohn's Disease, Crohn's Disease a form of inflammatory bowel disease., Diseases [C] - Digestive System Diseases [C06]
 
 
2022-003361-37: A Study of Etrasimod in Adults With Moderate-to-Severe Atopic Dermatitis, Who Have Tried Prior Systemic Treatments for Atopic Dermatitis. Studie přípravku Etrasimod u dospělých se středně těžkou až těžkou formou atopické dermatitidy, kteří dříve selhali na systémové léčbě atopické dermatitidy

Not yet recruiting
2/3
400
RoW
etrasimod, PF-07915503, Tablet
Pfizer Inc., Pfizer INc.
Moderate-to-Severe Atopic Dermatitis with a History of Prior Systemic Treatment Failure, Atopic Dermatitis, Diseases [C] - Immune System Diseases [C20]
 
 
NCT05033340: The Efficacy and Safety of Oral Etrasimod as Therapy for Moderately to Severely Active Crohn's Disease

Not yet recruiting
2/3
5
NA
Etrasimod, APD334, Placebo, PLEACEBO
Samia Hassan El-Shishtawy, Arena Pharmaceuticals
Crohn Disease
08/25
08/25
NCT05732454 / 2022-003361-37: A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Terminated
2/3
58
Europe, Canada, US, RoW
etrasimod, APD334, PF-07915503, Placebo
Pfizer, Pfizer INc.
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
04/24
04/24
VOYAGE, NCT04682639 / 2020-003226-23: A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

Completed
2
108
Europe, Canada, US, RoW
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Eosinophilic Esophagitis
09/22
06/23
NCT04556734: Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

Completed
2
80
Canada, US
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Alopecia Areata
06/23
06/23
2020-003226-23: A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with eosinophilic esophagitis

Not yet recruiting
2
96
Europe
Etrasimod, APD334, Tablet
Arena Pharmaceuticals Inc., Arena Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer Inc., Arena Pharmaceuticals Inc.
Eosinophilic Esophagitis (EoE), Eosinophilic esophagitis (EoE) a chronic, allergic inflammatory disease of the esophagus (the tube connecting the mouth to the stomach)., Diseases [C] - Digestive System Diseases [C06]
 
 
NCT05061446: Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Completed
2
54
Japan
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Ulcerative Colitis
10/23
10/23
GLADIATOR UC, NCT04607837 / 2020-003507-34: Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

Checkmark Initiation of GLADIATOR UC trial in ulcerative colitis
May 2021 - May 2021: Initiation of GLADIATOR UC trial in ulcerative colitis
Completed
2
234
Europe, Canada, US, RoW
Etrasimod, APD334, Placebo
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Ulcerative Colitis
06/24
06/24
NCT06521762: Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis

Recruiting
2
96
US
Etrasimod, VELSIPITY, Placebo, Corticosteroids
Yale University, Pfizer
Immune Checkpoint Inhibitor-Related Diarrhea and Colitis
12/28
12/28
NCT05287126: A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Recruiting
2
36
Europe, Japan, US
Etrasimod, APD334
Pfizer, Arena is a wholly owned subsidiary of Pfizer
Ulcerative Colitis
07/27
08/31
NCT03894163: A Phase I Study of Etrasimod in Healthy Chinese Audlt Subjects.

Recruiting
1
36
RoW
Etrasimod, Etrasimod Placebo
Everstar Therapeutics Limited
Healthy Volunteers
06/19
10/19
NCT06140290: A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Completed
1
8
Europe
Etrasimod Immediate Release (IR)
Pfizer
Healthy Participants
03/24
03/24
NCT05956002: A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants

Completed
1
16
Europe
Estraimod Immediate Release (IR), Etrasimod Mini Tab in water, Etrasimod Mini Tab in chocolate pudding, Etrasimod Mini Tab in yogurt, Etrasimod Mini Tab in applesauce
Pfizer
Healthy Participants
01/24
01/24
NCT06025227: Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.

Available
N/A
NA
Etrasimod
Pfizer, In Expanded Access, treating physicians are the Sponsors
Colitis, Ulcerative
 
 
EFFECT-UC, NCT06294925: A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

Recruiting
N/A
360
Europe, Canada
Etrasimod
Pfizer
Colitis, Ulcerative
04/27
05/27
ENDEAVOUR-UC, NCT06398626: An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Recruiting
N/A
300
US
Etrasimod
Pfizer
Colitis, Ulcerative
05/27
09/27
Trodelvy (sacituzumab govitecan-hziy) / Gilead
NCT04319198 / 2019-004868-22: Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Completed
4
25
Europe, US
Sacituzumab Govitecan-hiy, IMMU-132, Trodelvy™, GS-0132
Gilead Sciences, Immunomedics, Inc., Gilead Sciences Inc.
Metastatic Solid Tumor
10/24
10/24
2019-004868-22: Open-label Rollover Study to Assess Long-Term Safety in Subjects with Metastatic Cancers that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan.

Not yet recruiting
3
200
Europe
Sacituzumab govitecan, IMMU-132, hRS7-SN38, Lyophilisate for solution for infusion
Immunomedics, Inc., Gilead Sciences Inc, Immunomedics, Inc., Gilead Sciences Inc.
Metastatic Solid Tumors, Metastatic Cancer, Diseases [C] - Cancer [C04]
 
 
2019-004100-35: Therapy with an antibody-drug conjugate in patients with early HER2-negative breast cancer and high risk of relapse after neoadjuvant chemotherapy in primary HER2-negative breast cancer patients Therapie mit einem Antikörper-Wirkstoff-Konjugat bei Patienten mit frühem HER2-negativem Mammakarzinom und hohem Rückfallrisiko nach einer neoadjuvanten Chemotherapie bei primären HER2-negativen Brustkrebspatienten.

Ongoing
3
1200
Europe
Sacituzumab Govitecan, IMMU-132, Lyophilisate for solution for infusion
GBG Forschungs GmbH, Immunomedics, Inc, Gilead Sciences/Immunomedics, Inc
HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment HER2-negativem Brustkrebs und hohem Rückfallrisiko nach einer Standardbehandlung im neoadjuvanten Setting, HER2-negative breast cancer HER2-negativem Brustkrebs, Diseases [C] - Cancer [C04]
 
 
2021-003578-30: A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Estudio de sacituzumab govitecán frente a docetaxel en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado o metastásico

Not yet recruiting
3
580
Europe
Sacituzumab govitecan, Docetaxel, L01CD02, Powder for solution for infusion, Concentrate for solution for infusion, Docetaxel
Gilead Sciences, Inc., GILEAD SCIENCES INCORPORATED, Gilead Sciences, Inc.
Non-Small Cell Lung Cancer Cáncer de Pulmón No Microcítico, Non-Small Cell Lung Cancer Cáncer de Pulmón No Microcítico, Diseases [C] - Cancer [C04]
 
 
2022-000836-49: Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK-3475 for PD-L1 TPS ≥50% Metastatic NSCLC

Not yet recruiting
3
614
Europe
Solution for infusion, Powder for solution for infusion, KEYTRUDA (pembrolizumab, MK-3475), Trodelvy
Merck Sharp & Dohme LLC, MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.
First-line treatment of metastatic programmed cell death ligand 1 expressing (tumor proportion score ≥50%) non-small cell lung cancer, Previously untreated metastatic non-small cell lung cancer with tumors expressing PD-L1 ≥ 50%, Diseases [C] - Cancer [C04]
 
 
EVER-132-002, NCT04639986: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruiting
3
331
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Eribulin Mesylate Injection, Halaven, Capecitabine Oral Product, Xeloda, Gemcitabine Injection, Gemzar, Vinorelbine injection, Navelbine
Gilead Sciences, Iqvia Pty Ltd, Medidata Solutions, Parexel
Metastatic Breast Cancer
12/25
12/25
EVOKE-01, NCT05089734 / 2021-003578-30: Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Jan 2023 - Dec 2024: Data from EVOKE-01 trial for advanced or metaststic NSCLC in 2024
Hourglass Jan 2023 - Jun 2023 : Enrollment completion of EVOKE-01 trial for advanced or metaststic NSCLC
Active, not recruiting
3
603
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan-hziy (SG), IMMU-132, GS-0132, Docetaxel
Gilead Sciences, Gilead Sciences, Inc.
Non-Small Cell Lung Cancer
11/23
01/26
TROPiCS-04, NCT04527991 / 2020-002964-29: Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Jan 2024 - Dec 2024: Data readout from TROPiCS-04 trial for 2L metastatic urothelial cancer
Hourglass Jan 2021 - Jun 2021 : Regulatory submission in US for 3L urothelial carcinoma (based on TROPHY U-01 trial)
Active, not recruiting
3
696
Europe, Canada, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Paclitaxel, Taxol®, Docetaxel, Taxotere®, Vinflunine, Javlor ®
Gilead Sciences, Everest Medicines
Locally Advanced or Metastatic Unresectable Urothelial Cancer
10/25
10/25
ASCENT-GYN-01, NCT06486441: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (/GOG-3104/ENGOT-en26)

Recruiting
3
520
Europe, Canada, Japan, US, RoW
Sacituzumab govitecan-hziy, Trodelvy™, GS-0132, Doxorubicin, Adriamycin, Paclitaxel, Taxol
Gilead Sciences, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Endometrial Cancer
06/29
06/29
TROPiCS-02, NCT03901339 / 2018-004201-33: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Jul 2023 - Dec 2023: Regulatory decision in EU for HR+/HER2 breast cancer
Checkmark Approved for unresectable, locally advanced or metastatic HR+, HER2-ve metastatic breast cancer based on data from TROPiCS-02 study
Feb 2023 - Feb 2023: Approved for unresectable, locally advanced or metastatic HR+, HER2-ve metastatic breast cancer based on data from TROPiCS-02 study
Checkmark EMA validated MAA for Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
Jan 2023 - Jan 2023: EMA validated MAA for Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
More
Completed
3
543
Europe, Canada, US
Sacituzumab Govitecan-hziy, IMMU-132, GS-0132, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Gilead Sciences
Metastatic Breast Cancer
10/23
10/23
ISIdE, NCT05552001: Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

Recruiting
3
96
Europe
Sacituzumab govitecan, trodelvy
UNICANCER, Gilead Sciences
Triple Negative Breast Cancer, Metastatic Breast Cancer
05/26
05/28
ARIAN, NCT06431633: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Recruiting
3
129
Europe
Zimberelimab, anti-PD-1 monoclonal antibody AB122, Sacituzumab govitecan, Trodelvy, Cisplatin, Platinol, Carboplatin, Paraplatin
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma
11/31
11/31
EVOKE-SCLC-04, NCT06801834: Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Recruiting
3
695
Japan, US, RoW
Sacituzumab Govitecan (SG), Trodelvy®, GS-0132, IMMU 132, Topotecan, Amrubicin (Japan only)
Gilead Sciences
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
10/29
10/29
EA8231, NCT06524544: A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Sacituzumab Govitecan Alone in the Treatment of Advanced Urothelial Cancer

Not yet recruiting
3
384
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Questionnaire Administration, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy
National Cancer Institute (NCI)
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
12/28
12/28
ASCENT-07, NCT05840211: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan-hziy, Trodelvy™, GS-0132, IMMU-132, Paclitaxel, Taxol®, Nab-paclitaxel, Abraxane®, Capecitabine, Xeloda®
Gilead Sciences
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
09/25
12/28
KEYNOTE D46, NCT05609968 / 2022-000836-49: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Calendar Jan 2025 - Dec 2025: Market entry for mTNBC
Recruiting
3
614
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan, Trodelvy®, Pembrolizumab, MK-3475, Keytruda®
Merck Sharp & Dohme LLC, Gilead Sciences
Carcinoma, Non-Small-Cell Lung
01/27
08/28
ASCENT-04, NCT05382286 / 2021-005742-14: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting
3
443
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Pembrolizumab, KEYTRUDA®, Paclitaxel, Taxol®, nab-Paclitaxel, Abraxane®, Gemcitabine, Gemzar, Carboplatin
Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer, PD-L1 Positive
02/27
02/27
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ASCENT-05, NCT05633654: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Recruiting
3
1514
Europe, US, RoW
Sacituzumab govitecan-hziy (SG), GS-0132, IMMU-132, Trodelvy™, Pembrolizumab, KEYTRUDA®, Capecitabine, Xeloda
Gilead Sciences, Alliance Foundation Trials, LLC., NSABP Foundation Inc, GBG Forschungs GmbH
Triple Negative Breast Cancer
06/27
08/31
SWOG S1937, NCT04579224: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Recruiting
3
184
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy
National Cancer Institute (NCI)
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
08/30
08/30
ASCENT-03, NCT05382299 / 2021-005743-79: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Hourglass Jul 2024 - Dec 2024 : Data readout for 1L mTNBC (PD-L1)
Hourglass Aug 2024 - Dec 2024 : Data for 1L mTNBC (PD-L1-)
Recruiting
3
540
Europe, Canada, Japan, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Paclitaxel, nab-Paclitaxel, Abraxane®, Gemcitabine, Carboplatin
Gilead Sciences, Gilead Sciences, Inc
Triple Negative Breast Cancer, PD-L1 Negative
07/28
07/28
TROPHIT1, NCT06243393: Sacituzumab Govitecan in Metastatic Colorectal Cancer

Recruiting
2/3
80
Europe
Sacituzumab Govitecan (SG), Physicians Choice (PhC).
University Hospital Heidelberg
Metastatic Colorectal Cancer
08/28
02/29
2020-004844-27: Neoadjuvant sacituzumab govitecan to treat muscle-invasive bladder cancer Terapia neoadiuvante con sacituzumab govitecan per trattare cancro della vescica muscolo-infiltrante

Not yet recruiting
2
56
Europe
sacituzumab govitecan, [IMMU-132], Lyophilisate for solution for infusion
OSPEDALE SAN RAFFAELE, Immunomedics, Inc.
Muscle-invasive bladder cancer Cancro della vescica muscolo-infiltrante, Bladder cancer Cancro della vescica, Diseases [C] - Cancer [C04]
 
 
EVER-132-001, NCT04454437: Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Checkmark Approved in China for 2L metastatic TNBC
Jun 2022 - Jun 2022: Approved in China for 2L metastatic TNBC
Checkmark Submitted NDA in Hong Kong for the treatment of unresectable locally advanced or metastatic TNBC
Mar 2022 - Mar 2022: Submitted NDA in Hong Kong for the treatment of unresectable locally advanced or metastatic TNBC
Hourglass Aug 2021 - Dec 2021 : Submit BLA for metastatic TNBC in Taiwan and South Korea
More
Active, not recruiting
2
80
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132
Gilead Sciences, IQVIA RDS (Shanghai) Co., Ltd., Medidata Solutions, Q Squared Solutions (Beijing) Co., Ltd, Parexel
Metastatic Triple-negative Breast Cancer
08/21
12/25
2020-004876-16: SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy SURE-02: Studio di Fase 2, in aperto, a singolo braccio, con anticorpo immunoconiugato sacituzumab govitecan, in associazione a pembrolizumab, in pazienti con carcinoma uroteliale della vescica muscolo-infiltrante che non possono ricevere o che rifiutano la chemioterapia con cisplatino.

Ongoing
2
48
Europe
Pembrolizumab, Sacituzumab Govitecan, [NA], [IMMU-132], Solution for infusion, Lyophilisate for solution for infusion, KEYTRUDA (Pembrolizumab, MK-3475)
OSPEDALE SAN RAFFAELE, Merck Sharp & Dohme Corp., Immunomedics, Inc.
muscle-invasive bladder cancer Carcinoma uroteliale della vescica muscolo infiltrante, muscle-invasive bladder cancer Carcinoma uroteliale della vescica muscolo infiltrante, Diseases [C] - Cancer [C04]
 
 
2019-000579-18: A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Un estudio de sacituzumab govitecan (IMMU-132) en pacientes con tumores sólidos metastásicos

Not yet recruiting
2
420
Europe
sacituzumab govitecan, Powder for solution for infusion, Trodelvy
Gilead Sciences, Inc., Gilead Sciences, Inc.
Metastatic Solid Tumors Tumores sólidos metastásicos, Metastatic Solid Tumors Tumores sólidos metastásicos, Diseases [C] - Cancer [C04]
 
 
2021-003669-36: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruiting
2
280
Europe
BAVENCIO, sacituzumab govitecan, MSB0010718C, IMMU-132, M6223, NKTR-255, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, BAVENCIO, Trodelvy
Merck Healthcare KGaA, MERCK KGAA, Merck Healthcare KGaA
Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy., Bladder cancer, Diseases [C] - Cancer [C04]
 
 
2022-001397-61: Clinical trial phase II with Sacituzumab govitecan in Patients with Metastatic Triple-Negative Breast Cancer Ensayo clínico fase II con Sacituzumab govitecan para pacientes con cancer de mama triple negativo

Not yet recruiting
2
50
Europe
Trodelvy, EU/1/21/1592/001, Powder for concentrate for solution for infusion
Medica Scientia Innovation Research SL., Gilead Sciencies SLU
Advanced triple-negative breast cancer Cáncer de mama triple negativo avanzado, Advanced triple-negative breast cancer (TNBC) Cáncer de mama triple negativo avanzado (TNBC), Diseases [C] - Cancer [C04]
 
 
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
SURE-01, NCT05226117: Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Recruiting
2
44
Europe
Sacituzumab govitecan
IRCCS San Raffaele, High Research
Urothelial Carcinoma
06/25
06/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
NCT04251416: A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Recruiting
2
50
US
Sacituzumab Govitecan, IMMU-132
Yale University, Gilead Sciences
Endometrial Carcinoma
12/25
02/26
NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting
2
40
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
08/26
NCT06178588: Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Recruiting
2
22
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
University of Kansas Medical Center, National Cancer Institute (NCI)
Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
11/25
11/26
ACROSS-TROP2, NCT06236269: HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

Recruiting
2
50
Europe
Sacituzumab Govitecan, Trodelvy
SOLTI Breast Cancer Research Group
Breast Cancer Stage IV
02/26
02/27
NCT05675579: A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Recruiting
2
25
US
Sacituzumab Govitecan, (IMMU-132) Immunomedics, Pembrolizumab, KEYTRUDA®
M.D. Anderson Cancer Center, Gilead Sciences
Breast Cancer
12/26
12/26
Saci-IO TNBC, NCT04468061: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Hourglass Jan 2022 - Jun 2022 : Initiation of P3 trial in combination with keytruda for 1L mTNBC
Recruiting
2
110
US
Sacituzumab Govitecan, IMMU-132, Trodelvy, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Gilead Sciences, Merck Sharp & Dohme LLC
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
04/26
04/29
NCT06248515: A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Recruiting
2
18
US
Sacituzumab govitecan-hziy
Georgetown University, Gilead Sciences
Thymoma, Thymic Carcinoma
04/26
12/26
TROPICS-03, NCT03964727 / 2019-000579-18: Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

Hourglass Jun 2023 - Jun 2023 : Presentation of data from TROPiCS-03 trial for advanced/metastatic endometrial cancer at ASCO 2023
Hourglass Jan 2022 - Dec 2022 : From TROPiCS-03 trial for NSCLC
Active, not recruiting
2
227
Europe, Canada, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, GS-0132
Gilead Sciences, Gilead Sciences, Inc.
Metastatic Solid Tumor
01/25
09/25
NCT04986579: Scalp Cooling in MBC

Recruiting
2
120
US
Paxman Scalp Cooling System, Scalp Cooling Cap, Eribulin, Halaven, Sacituzumab govitecan, Trodelvy, IMMU-132, Trastuzumab deruxtecan, Enhertu, DS-8201a
Dana-Farber Cancer Institute, Paxman Coolers Limited, AstraZeneca, Eisai Inc., Daiichi Sankyo, Gilead Sciences
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
06/26
06/28
NCT06462079: Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Not yet recruiting
2
43
NA
Sacituzumab Govitecan, Trodelvy, Radiotherapy
Guangzhou Medical University
Brain Metastasis
01/27
07/27
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
NCT06477419: A Study of Sacituzumab Govitecan in People With Mesothelioma

Recruiting
2
33
US
Sacituzumab govitecan-hziy
Memorial Sloan Kettering Cancer Center, Gilead Sciences
Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
06/29
06/29
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Laura Huppert, MD, BA, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/26
06/26
TROPHY-U-01, NCT03547973 / 2018-001167-23: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Hourglass Jun 2023 - Jun 2023 : Presentation of data from TROPHY U-01 trial for metastatic urothelial cancer at ASCO 2023
Checkmark Approved in US for 3L metastatic urothelial cancer
Apr 2021 - Apr 2021: Approved in US for 3L metastatic urothelial cancer
Checkmark Data from TROPHY U-01 study in combination with pembrolizumab for 2L metastatic urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: Data from TROPHY U-01 study in combination with pembrolizumab for 2L metastatic urothelial cancer at ESMO 2020
More
Recruiting
2
827
Europe, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, Pembrolizumab, KEYTRUDA®, Cisplatin, Avelumab, BAVENCIO®, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
Gilead Sciences, Merck KGaA, Darmstadt, Germany
Metastatic Urothelial Cancer
06/30
06/30
NCI-2018-02551, NCT03725761: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Active, not recruiting
2
31
US
Sacituzumab Govitecan, IMMU-132
University of Wisconsin, Madison, National Cancer Institute (NCI), Gilead Sciences
Prostate Cancer
04/24
09/27
ELEVATE TNBC, NCT04958785: Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Terminated
2
92
Europe, US, RoW
Magrolimab, GS-4721, Nab-Paclitaxel, Abraxane, Paclitaxel, Taxol®, Sacituzumab Govitecan-hziy, GS-0132, Trodelvy®
Gilead Sciences
Triple-Negative Breast Cancer
10/24
10/24
EVOKE-02, NCT05186974 / 2021-004280-27: Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Hourglass Jul 2021 - Jun 2022 : Market entry for mTNBC
Active, not recruiting
2
193
Europe, Canada, US, RoW
Sacituzumab Govitecan-hziy (SG), GS-0132, IMMU-132, Pembrolizumab, KEYTRUDA®, Carboplatin, Paraplatin®, Cisplatin, Platinol®
Gilead Sciences, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
02/26
02/26
SG-ESCC, NCT06329869: Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
35
RoW
Sacituzumab govitecan
National Taiwan University Hospital, Gilead Sciences
Esophageal Squamous Cell Carcinoma
11/26
11/27
SMART, NCT06161532: Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors () Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Recruiting
2
60
US
Sacituzumab govitecan, Atezolizumab
National Cancer Institute (NCI)
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract, Primary Adenocarcinoma of the Bladder, Primary Adenocarcinoma of the Urinary Tract, Renal Medullary Carcinoma, Squamous Cell Carcinoma of the Penis
11/27
11/28
SETHY, NCT06235216: Sacituzumab govitEcan in THYroid Cancers

Recruiting
2
42
Europe
Sacituzumab govitecan, Trodelvy
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
12/27
12/27
NCT06739395: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting
2
300
RoW
Olaparib tablet, Temozolomide capsule, Anlotinib, Trametinib tablet, Dabrafenib, Vebreltinib Enteric Capsules, Alpelisib Pill, Sacituzumab Govitecan-Hziy 180 MG, Lenvatinib Capsules, Pazopanib Pill, Palbociclib Pill, Chidamide, PD-1/PD-L1/PD-1&CTLA4 inhibitor, Target Gene
Tianjin Medical University Second Hospital
Solid Tumor, Precision Medicine
12/26
05/27
NCT06682728: Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Recruiting
2
23
US
Sacituzumab Govitecan (SG), Nivolumab
University of California, Irvine, Gilead Sciences
Urothelial Carcinoma, Muscle-invasive Bladder Cancer
12/26
12/26
preSAVE, NCT06528483: Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

Not yet recruiting
2
63
Europe
Sacituzumab Govitecan + Zimberelimab, TRODELVY, AB122
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Gilead Sciences
Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm, Muscle-Invasive Bladder Carcinoma
12/26
12/29
NCT06878625: A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Recruiting
2
138
RoW
Sacituzumab Govitecan combined with Toripalimab, Sacituzumab govitecan combined with anti-angiogenesis
Tianjin Medical University Cancer Institute and Hospital
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
06/27
06/27
NCT06667167: First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

Recruiting
2
21
RoW
Induction Carboplatin, Carboplatin, Etoposide, Pembrolizumab, Sacituzumab Govitecan
Nir Peled
NSCLC (non-small Cell Lung Cancer)
11/27
11/28
NCI-2018-01581, NCT03606967: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
2
70
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Personalized Synthetic Long Peptide Vaccine, Personalized SLP Vaccine, TSMA-based SLP Vaccine, TSMA-based Synthetic Long Peptide Vaccine, Tumor Specific Mutant Antigen-based Synthetic Long Peptide Vaccine, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
11/25
11/25
NCT05884320: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Recruiting
2
30
US
Sacituzumab Govitecan
M.D. Anderson Cancer Center, Gilead Sciences
Gland, Salivary Gland Cancers
12/25
12/26
NCT06133517: PeRioperative Immunotherapy Combined with Sacituzumab Govitecan in Muscle Invasive BlAdder Cancer

Recruiting
2
70
Europe
Sacituzumab govitecan, Trodelvy, Zimberelimab, Domvanalimab
Fundación para el Progreso de la Oncología en Cantabria, Apices Soluciones S.L.
Urothelial Bladder Carcinoma
12/30
12/30
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
06/25
07/26
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Active, not recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
NCT06311214: Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Recruiting
2
500
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Electronic Health Record Review, Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG 22CE, ASG-22CE, ASG22CE, Enfortumab Vedotin-ejfv, Padcev, Immunohistochemistry Staining Method, Cell/Tissue, Immunohistochemistry, IHC, Immunohistochemistry, Immunohistochemistry (IHC), Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
03/28
03/28
NCT06665178: Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Recruiting
2
20
Canada
Sacituzumab Govitecan
British Columbia Cancer Agency, Gilead Sciences
Breast Cancer
05/27
12/28
TROP2, NCT06923826: Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

Not yet recruiting
2
32
RoW
Sacituzumab govitecan, Trodelvy
National University Hospital, Singapore, Gilead Sciences
Salivary Gland Cancer, Thyroid Cancer
04/30
04/30
NCT06401824: Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Recruiting
2
25
Europe
Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab, sacituzumab govitecan; zirabev
Maastricht University Medical Center, Gilead Sciences
NSCLC Stage IV, Brain Metastases, Adult
11/26
04/27
Saci-IO HR+, NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Hourglass Jan 2021 - Jan 2021 : Data from trial for HR+ / HER2 – metastatic breast cancer
Active, not recruiting
2
110
US
Pembrolizumab, Keytruda, Sacituzumab Govitecan, TRODELVY
Ana C Garrido-Castro, MD, Merck Sharp & Dohme LLC, Gilead Sciences
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
03/24
06/27
NCT07040644: A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Not yet recruiting
2
150
RoW
Sacituzumab Govitecan (SG), Toripalimab, Nab-paclitaxel
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple Negative Breast Neoplasms
06/27
06/28
NCT06865677: Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Suspended
2
95
US
Sacituzumab govitecan
National Cancer Institute (NCI)
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
04/27
12/27
 

Download Options